How To Calculate Impurity Limits As Per Ich Excel

Calculate impurity limits according to ICH Q3A/Q3B guidelines for pharmaceutical substances

Comprehensive Guide to Calculating Impurity Limits as per ICH Q3A/Q3B Guidelines

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides comprehensive guidelines for controlling impurities in pharmaceutical substances and products. The ICH Q3A (Impurities in New Drug Substances) and Q3B (Impurities in New Drug Products) guidelines establish thresholds for reporting, identifying, and qualifying impurities based on the maximum daily dose of the drug substance.

Understanding ICH Impurity Classification

ICH classifies impurities into three main categories:

1. Organic Impurities: Process-related impurities (intermediates, by-products) and degradation products
2. Inorganic Impurities: Reagents, ligands, catalysts, heavy metals, inorganic salts
3. Residual Solvents: Volatile chemicals used in manufacturing (covered separately in ICH Q3C)

Key Thresholds in ICH Guidelines

The ICH establishes four critical thresholds based on maximum daily dose:

Threshold Type	≤2g/day	>2g/day	ICH Reference
Reporting Threshold	0.05%	0.03%	Q3A(R2) 2.4
Identification Threshold	0.10% or 1.0 mg/day (lower)	0.05%	Q3A(R2) 2.5
Qualification Threshold	0.15% or 1.0 mg/day (lower)	0.05%	Q3A(R2) 2.6

Step-by-Step Calculation Process

1. Determine Maximum Daily Dose

   The foundation of all impurity calculations is the maximum daily dose (MDD) of the drug substance. This is typically expressed in milligrams per day (mg/day). For example, if a drug is administered as 500mg tablets with a maximum of 2 tablets per day, the MDD would be 1000mg/day.

2. Identify Applicable Thresholds

   Based on the MDD, determine which threshold values apply:

   • For MDD ≤ 2g/day: Use standard thresholds (0.05%, 0.10%, 0.15%)
   • For MDD > 2g/day: Use reduced thresholds (0.03%, 0.05%, 0.05%)
3. Calculate Absolute Values

   Convert percentage thresholds to absolute values (mg/day) by multiplying the percentage by the MDD. For example, with a 1000mg/day dose:

   • Reporting threshold: 1000 × 0.0005 = 0.5 mg/day
   • Identification threshold: 1000 × 0.001 = 1.0 mg/day (or 0.1% whichever is lower)
   • Qualification threshold: 1000 × 0.0015 = 1.5 mg/day (or 1.0 mg/day whichever is lower)
4. Consider Route of Administration

   The route of administration can affect impurity limits, particularly for:

   • Parenteral products: Typically require stricter limits due to bypassing first-pass metabolism
   • Inhalation products: May have specialized requirements due to direct lung exposure
   • Topical products: Often have different considerations based on absorption potential
5. Apply Toxicity Factors

   For impurities with known toxicity, additional safety factors may apply:

   Toxicity Level	Example Compounds	Typical Safety Factor
   Class 1 Solvents (High Toxicity)	Benzene, Carbon Tetrachloride	100-1000x
   Class 2 Solvents (Medium Toxicity)	Acetonitrile, Chlorobenzene	10-100x
   Class 3 Solvents (Low Toxicity)	Acetone, Ethanol	1-10x

6. Document Justification

   All calculations and decisions regarding impurity limits must be thoroughly documented with scientific justification, particularly when:

   • Applying higher thresholds than standard
   • Using alternative calculation methods
   • Justifying why certain impurities don’t require qualification

Special Considerations for Different Impurity Types

Organic Impurities

Organic impurities are typically the most common and can originate from:

• Starting materials: Unreacted materials or by-products from synthesis
• Degradation products: Formed during storage (e.g., oxidative degradation)
• Intermediates: Partially reacted materials from multi-step syntheses

For organic impurities, the ICH Q3A guidelines provide specific decision trees for qualification based on:

• Daily exposure (mg/day)
• Duration of treatment
• Similarity to qualified impurities

Inorganic Impurities

Inorganic impurities often require specialized analytical techniques and may include:

• Heavy metals: Typically controlled to <10 ppm unless justified otherwise
• Reagents and ligands: Such as palladium catalysts or boron reagents
• Inorganic salts: Like sodium chloride or potassium phosphate

The ICH Q3D guideline provides specific limits for elemental impurities, categorized by:

• Class 1 (Cd, Pb, As, Hg): Highest concern
• Class 2A (Co, V, Ni): Route-dependent limits
• Class 2B (Ag, Au, Ir, etc.): Lower concern
• Class 3 (Ba, Cr, Cu, etc.): Permitted daily exposure limits

Residual Solvents

Residual solvents are governed by ICH Q3C, which classifies them into three classes:

Class	Toxicity Concern	Examples	Typical Limits
1	Known human carcinogens or strong environmental hazards	Benzene, Carbon tetrachloride	2-8 ppm
2	Non-genotoxic animal carcinogens or possible causative agents	Acetonitrile, Chlorobenzene	50-3880 ppm
3	Low toxic potential	Acetone, Ethanol, Heptane	500-5000 ppm

Regulatory Expectations and Documentation

Regulatory agencies expect comprehensive documentation of impurity control strategies, including:

• Development Studies: Data showing how impurities were identified and controlled during development
• Analytical Methods: Validated methods for detecting and quantifying impurities
• Specification Justification: Scientific rationale for chosen acceptance criteria
• Batch Analysis Data: Results from multiple batches demonstrating consistent control
• Stability Data: Information on how impurities change over time under various conditions

The FDA’s guidance on impurities emphasizes that “the applicant should summarize the actual and potential impurities most likely to arise during the synthesis, purification, and storage of the new drug substance.” Similarly, the ICH Q3A(R2) guideline provides the official thresholds and decision trees used worldwide.

Common Challenges and Solutions

Pharmaceutical developers often face several challenges when implementing ICH impurity guidelines:

Challenge 1: Impurities Below Detection Limits

Problem: Some impurities may exist below the detection limits of available analytical methods.

Solution:

• Use more sensitive techniques (e.g., LC-MS/MS instead of HPLC-UV)
• Develop and validate methods with lower LOQ/LOD
• Provide scientific justification if impurities cannot be detected

Challenge 2: Genotoxic Impurities

Problem: Impurities with genotoxic potential require much lower limits (often in ppm range).

Solution:

• Apply the principles of ICH M7 for mutagenic impurities
• Use TTC (Threshold of Toxicological Concern) concept when appropriate
• Implement specific controls in manufacturing to prevent formation

Challenge 3: Polymorphic Forms

Problem: Different polymorphic forms may have different impurity profiles.

Solution:

• Characterize impurity profiles for all polymorphic forms
• Ensure specifications cover all potential forms
• Monitor for form changes during stability studies

Case Study: Applying ICH Guidelines to a Small Molecule Drug

Consider a new oral drug with:

• Maximum daily dose: 250 mg
• Treatment duration: Chronic (>6 months)
• Three identified impurities at levels of 0.06%, 0.12%, and 0.20%

Step 1: Determine Thresholds

Since MDD = 250 mg (<2g/day), we use standard thresholds:

• Reporting: 0.05% (0.125 mg/day)
• Identification: 0.10% (0.25 mg/day)
• Qualification: 0.15% (0.375 mg/day)

Step 2: Evaluate Each Impurity

Impurity	Level (%)	Level (mg/day)	Actions Required
A	0.06%	0.15 mg	Report only (below identification threshold)
B	0.12%	0.30 mg	Report and identify (above 0.10%)
C	0.20%	0.50 mg	Report, identify, and qualify (above 0.15%)

Step 3: Qualification Strategy

For Impurity C (0.20%), which exceeds the qualification threshold:

1. Conduct toxicological assessment (literature search, in silico prediction)
2. If no concern, justify why qualification studies aren’t needed
3. If concern exists, conduct appropriate safety studies
4. Set specification limit based on qualification data

Emerging Trends in Impurity Control

The field of impurity control is evolving with several important trends:

• Advanced Analytical Techniques: HRMS, NMR, and other high-resolution techniques enabling detection of impurities at ppb levels
• In Silico Toxicology: Computational tools for predicting impurity toxicity (e.g., Derek Nexus, Sarah Nexus)
• Continuous Manufacturing: Real-time monitoring of impurities during manufacturing
• ICH Q12: New guidelines on lifecycle management of analytical procedures
• Mutagenic Impurity Control: Increased focus on control strategies for potential mutagenic impurities

The EMA’s implementation of ICH M7 provides valuable insights into current expectations for controlling mutagenic impurities, which often require limits as low as 1.5 μg/day (the TTC for most compounds).

Best Practices for Implementation

1. Early Assessment

   Begin impurity profiling early in development to identify potential issues before they become critical.

2. Robust Analytical Methods

   Develop and validate methods that can detect all potential impurities at required levels.

3. Comprehensive Documentation

   Maintain thorough records of all impurity-related studies and decisions.

4. Regulatory Dialogue

   Engage with regulatory agencies early to discuss any non-standard approaches.

5. Continuous Monitoring

   Monitor impurity profiles throughout the product lifecycle, including stability studies.

6. Risk-Based Approach

   Apply risk assessment principles to focus resources on the most critical impurities.

Frequently Asked Questions

Q: What if an impurity is below the reporting threshold?

A: Impurities below the reporting threshold (typically 0.05% for doses ≤2g/day) do not need to be reported in regulatory submissions, though they should still be monitored internally as part of good manufacturing practice.

Q: How are impurities in excipients handled?

A: Excipient impurities are generally controlled by pharmacopeial monographs (USP, EP, JP). However, if an excipient contributes significantly to the total impurity burden of the drug product, additional controls may be needed.

Q: What about impurities formed during storage?

A: Degradation products formed during storage are considered impurities and must be controlled according to ICH guidelines. Stability studies should identify and characterize these impurities.

Q: Can we use higher thresholds for short-term treatments?

A: The ICH guidelines don’t provide different thresholds based on treatment duration, but the qualification requirements may be less stringent for short-term treatments. This should be justified on a case-by-case basis.

Q: How do we handle impurities that are also active ingredients?

A: When an impurity is also an active ingredient (e.g., a degradation product with pharmacological activity), different considerations apply. These should be controlled as part of the active substance rather than as impurities.